ArticleKidney international reports2026
Data-Driven Clustering of Secretory Bone and Inflammatory Markers to Subphenotype Patients Undergoing Hemodialysis.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Parathyroid hormone (PTH) remains the primary biomarker used to classify and monitor chronic kidney disease-mineral and bone disorder (CKD-MBD); nonetheless, its reliability for risk stratification and treatment guidance is limited. Multidimensional biomarker clustering that integrates indicators of bone turnover, vascular calcification, inflammatory and oxidative stress may better capture the heterogeneity of clinical phenotypes, improve risk stratification, and inform on new therapeutic approaches in dialysis care. Methods: We conducted a computational analysis of a multicentric cohort study including 471 patients undergoing hemodialysis. The Partitioning Around Medoids algorithm was used to cluster the cohort by a pathophysiology-based biomarker panel (noxPTH, intact parathyroid hormone [iPTH], osteoprotegerin [OPG], soluble receptor activator of nuclear factor-κB ligand [sRANKL], antioxidative capacity [ImAnOx], oxidative capacity [PerOx], β-Crosslaps [β-CL], and high-sensitivity C-reactive protein [hsCRP]) at baseline. The cluster phenotypes were characterized by anthropometrics, imaging, and clinical data. Cluster-specific outcomes and event patterns were assessed after 1 year. Results: A total of 4 distinct clusters were identified. Cluster 1 reflected a high bone turnover state with high antioxidative capacity and high bone-specific alkaline phosphatase. Cluster 2 showed low bone turnover with high antioxidative capacity and high sclerostin levels. Cluster 3 exhibited an inflammatory-oxidative phenotype and the highest 1-year mortality; cluster membership improved prediction of events beyond clinical covariates. This phenotype was marked by high aortic calcium burden, vascular disease, markers of vitamin D degradation, low vaccine response, and hepatic steatosis. Cluster 4 showed a balanced biomarker profile and the highest rate of reclassification after 1 year. Conclusion: Multidimensional biomarker clustering captures heterogeneity in bone and vascular disease phenotypes of CKD-MBD, exhibiting differential mortality risk and event patterns and highlighting inflammation as an important pathway for further studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.